GlassScriptPhysician profile
Alan L Gass
NPI 1306847603
$216,115.70
in general payments reported to CMS, 2019-2025
24 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $20K · 2021: $21K · 2022: $39K · 2023: $36K · 2024: $38K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $50K · Consulting Fee: $20K · Travel and Lodging: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,272 · Food and Beverage: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $49,950.00 |
| Consulting Fee | $20,168.75 |
| Travel and Lodging | $15,695.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,271.58 |
| Food and Beverage | $2,457.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $107,214.99 | 2020-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $48,298.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $26,791.71 | 2020-2022 | |
| Abbott Laboratories | $19,785.29 | 2019-2025 | Cardiomems, 2nd Gen Centrimag Primary Console |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7,536.20 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,304.46 | 2023-2024 | Jardiance |
| Bridgebio Pharma, INC. | $214.53 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $169.80 | 2020-2022 | |
| Medtronic Vascular, INC. | $169.46 | 2019 | |
| Ethicon US, LLC | $121.73 | 2019 | |
| Cook Medical LLC | $95.52 | 2024 | Zenith Spiral-Z |
| Merck Sharp & Dohme LLC | $80.70 | 2022-2024 | Verquvo |
| Pfizer INC. | $71.89 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.17 | 2023-2024 | Camzyos |
| Alexion Pharmaceuticals, INC. | $36.41 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.26 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $25.80 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.39 | 2023 | Amvuttra |
| Getinge USA Sales, LLC | $24.49 | 2019 | |
| Scpharmaceuticals INC. | $24.12 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $15.15 | 2024 | |
| Biotronik INC. | $12.39 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Gass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.